Artiva Biotherapeutics Cancels ACR Convergence 2026 Data Presentation And November 9 Investor Webcast Following AlloNK Development Discontinuation
Clinical Development Discontinuation and Patient Follow-UpUpdated clinical response data from patients receiving AlloNK in combination with rituximab continued to demonstrate deep B cell depletion and clinical activity
Artiva stopped developing a medicine called AlloNK and canceled its big conference presentation. When a company stops a medicine project, it means that project wasn't working out the way they hoped.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.